We are live on ! Find out more

Compass Pathways

CMPS

Market cap $1.59B

11.50 USD

-0.69

5.66%

At close Updated Oct 30, 11:54 AM EDT

1 day

-5.66%

5 days

1.86%

1 month

-7.56%

3 months

-0.61%

6 months

26.93%

Year to date

75.57%

1 year

82.54%

5 years

-73.29%

10 years

-60.34%

About: Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.

Employees: 156

Healthcare Medical Care Facilities

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 34.3%

Neutral 65.7%

Negative 0%

Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place in Colorado Springs, CO, from November 5-8. The Company will feature its Change the Tune in TRD educational campaign for U.S. HCPs focused on TRD, as well as encore presentations from its COMP360.

Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress

Compass Pathways: A Compelling Opportunity In A Large And Underserved Market

COMPASS Pathways is currently engaged in a rolling submission and review with the FDA for COMP360 and expects a commercial launch in the first half of 2027. COMPASS is initially targeting the TRD market, which is large and underserved. SPRAVATO has already established the commercial potential of this market, and COMP360 could benefit from reduced dosing frequency. Recent industry M&A also validates the commercial potential of psychedelics, although competitive dynamics and reimbursement are key risks.

Compass Pathways: A Compelling Opportunity In A Large And Underserved Market

Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 3, 2026. A live webcast of the call will be available.

Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026

Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales

COMPASS Pathways is rated Buy, with high risk, based on strong trial design and imminent FDA review for COMP360 in treatment-resistant depression. COMP360's Phase 3 trials matched FDA guidance, achieved statistically significant efficacy similar to Spravato, and are positioned for a fast-track FDA decision this quarter. CMPS holds $433.3 million in cash, funding operations into 2028, with valuation implying investors pay 0.57x Spravato's annual sales for COMP360's TRD opportunity.

Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the first-ever TRD Awareness Day in the U.S., a day dedicated to recognizing and advocating for individuals, caregivers and communities impacted by TRD. The campaign is being amplified by leading mental health organizations, including National Alliance on Mental Illness (NAMI), Mental Health.

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and re.

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways Appoints Kelley Boucher as Chief People Officer

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee.

Compass Pathways Appoints Kelley Boucher as Chief People Officer

Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch

Compass Pathways NASDAQ: CMPS executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling.

Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch

Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data

Compass Pathways NASDAQ: CMPS said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin treatment in treatment-resistant depression, or TRD.

Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data

Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances

Compass Pathways NASDAQ: CMPS expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global Healthcare Conference.

Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances

See News Rankings

Price charts implemented using Lightweight Charts™